Syros to Participate in Upcoming Investor Conferences in March

Rhea-AI Summary

Syros Pharmaceuticals (NASDAQ:SYRS) announces participation in three investor conferences. The Cowen and Company 41^st Annual Health Care Conference on March 1 will feature a panel titled Novel Oncology Targets at 1:20 p.m. ET. The 33^rd Annual Roth Conference on March 15 will discuss Navigating Clinical Development in RARE Hematologic & Inflammatory Disease at 10:00 a.m. ET. Lastly, the Oppenheimer 31^st Annual Healthcare Conference will occur on March 16, starting at 8:40 a.m. ET. Live webcasts will be available on the Syros website.

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that members of its management team will participate in panel discussions and present a corporate overview at upcoming investor conferences. Details are as follows:

Cowen and Company 41^st Annual Health Care Conference
Date: Monday, March 1
Panel Title: Novel Oncology Targets
Panel Time: 1:20 p.m. ET

33^rd Annual Roth Conference
Date: Monday, March 15
Panel Title: Navigating Clinical Development in RARE Hematologic & Inflammatory Disease
Panel Time: 10:00 a.m. ET

Oppenheimer 31^st Annual Healthcare Conference
Date: Tuesday, March 16
Presentation Time: 8:40 a.m. ET

Live webcasts of the Roth and Oppenheimer presentations will be available on the Investors & Media section of the Syros website at www.syros.com. Archived replays of the webcasts will be available for approximately 30 days following each presentation.

About Syros Pharmaceuticals

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust clinical-stage pipeline, including: SY-1425, a first-in-class oral selective RARα agonist in RARA-positive patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide in patients with acute promyelocytic leukemia; and SY-5609, a highly selective and potent oral CDK7 inhibitor in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005882/en/

FAQ

What is Syros Pharmaceuticals presenting at the Cowen and Company Conference on March 1, 2023?

Syros Pharmaceuticals will present a panel titled 'Novel Oncology Targets' at 1:20 p.m. ET.

When is the 33rd Annual Roth Conference and what is Syros Pharmaceuticals' agenda?

The 33rd Annual Roth Conference will be on March 15, 2023, featuring a panel on 'Navigating Clinical Development in RARE Hematologic & Inflammatory Disease' at 10:00 a.m. ET.

What time will Syros Pharmaceuticals present at the Oppenheimer Healthcare Conference?

Syros Pharmaceuticals will present at the Oppenheimer 31st Annual Healthcare Conference on March 16, 2023, at 8:40 a.m. ET.

Where can I watch the live webcasts of Syros Pharmaceuticals' presentations?

Live webcasts will be available on the Investors & Media section of the Syros website.

What drugs is Syros Pharmaceuticals developing?

Syros is developing SY-1425, SY-2101, and SY-5609, targeting various hematologic and oncology indications.